This morning Bigfoot BioMedical and Abbott (NYSE: ABT) announced the following;
“Abbott (NYSE: ABT) and Bigfoot Biomedical today announced that the companies have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle® Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States.”
This is a major step forward for Bigfoot as they move ever closer to bringing their version of a closed loop insulin delivery system to market. It also comes at a time when the insulin pump world is about to transform yet again. It’s no secret that . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.